RLF AgTech Ltd (ASX:RLF) | RLF Hits Milestone for Axioma After 3-Year Grower Program
MarketOpen's Trading Titan podcast. Episode: RLF AgTech Ltd (ASX: RLF). Announcement Type: Operational Update – Commercial Milestone for the Axioma Biologicals Range.
RLF AgTech Ltd has completed a three-year commercial development program for its Axioma Biologicals range with a major Australian corporate grain grower. According to the company, the program progressed from initial field evaluation through commercial demonstration to large-scale commercial adoption across cereal and canola production.
The company reports positive yield responses across the majority of paddocks assessed over three growing seasons, with the strongest and most consistent results achieved in wheat. According to RLF, the grower has substantially increased adoption of Axioma Biologicals during the current season.
RLF says the program has established a repeatable commercial development framework that it intends to apply with additional corporate growers across Australia. The company also continues to evaluate Australian manufacture of the Axioma Biologicals range, stating that local production has the potential to improve supply reliability, shorten lead times and better utilise its domestic manufacturing capability as demand grows.
The announcement also references independent industry research estimating the global biostimulants market at approximately four to five billion US dollars annually.
Key topics covered in this episode include the three-year commercial development program, the progression from field evaluation to commercial adoption, the reported on-farm results, the company's plans to expand the commercial development model with additional corporate growers, and its evaluation of Australian manufacture for the Axioma Biologicals range.
According to the company, the next steps are to apply the staged commercial development model with additional corporate growers across Australia, continue expanding adoption of the Axioma Biologicals range, and continue evaluating Australian manufacture of the Axioma Biologicals range.
This episode is for information purposes only. Nothing in this podcast constitutes financial advice. Listeners should conduct their own research and consider their personal financial circumstances before making any investment decision.